intensified preconditioning is required to ensure long-term survival, 4 which usually is not possible in elderly patients. However, in contrast to traditional allo-HSCT, related allogeneic hematopoietic stem cell micro-transplantation has been shown to be feasible and effective in elderly patients with AML. 5 We treated a 59-year-old man with AMAL with auto-HSCT followed by allogeneic hematopoietic stem cell microtransplantation. He was admitted in November 2011 with 1-month history of a neck mass. Routine blood tests on admission showed a WBC count of 2.4 × 10 9 /L, hemoglobin 8.5 g/dL and platelets 146 × 10 9 /L. A BM aspirate revealed 32.5% blast cells. The immunophenotyping results showed that blast cells were positive for HLA-DR, CD15, mCD19, CD22, CD33, CD117, MPO and cCD22. Fusion gene screening proved positive for AML/ETO. The patient was diagnosed with AMAL, and chemotherapy with vincristine, daunorubicin, Ara-C and prednisone (VDAP regimen) was initiated in December 2011. The patient achieved CR after chemotherapy. He subsequently received two cycles of chemotherapy as consolidation, including one cycle of Ara-C plus PEGasparaginase and one cycle of fludarabine, Ara-C and G-CSF (FLAG). Because of his advanced age, he and his relatives opted for auto-HSCT rather than allo-HSCT. In May 2012, the patient received mobilization with mitoxantrone, vincristine, Ara-c, dexamethasone and MTX. PMNCs (9.12 × 10 9 /kg) and CD34 The AML/ETO fusion gene is associated with good prognosis in patients with AML, and chemotherapy but not allo-HSCT is generally recommended in AML/ETO-positive patients. However, the situation differs in patients with AMAL. The survival times of two patients with AML/ETO-positive AMAL were only 1.5 and 7 months, respectively, 2 indicating that AML/ETO is not an indicator of good prognosis in patients with AMAL.
Micro-transplantation of G-CSF-mobilized allogeneic PMNCs has proven effective in elderly patients with AML, both in terms of prolonging disease-free survival and accelerating neutrophil and platelet recoveries after chemotherapy. 5 Its effectiveness has been further demonstrated in young patients with AML. 7 However, its effects in patients with ALL or AMAL have not previously been reported. We supposed that G-CSF-mobilized donor PMNCs may be beneficial in this patient with AMAL, as confirmed by the prolonged disease-free survival (nearly 2 years) without allo-HSCT, the disappearance of clusters of immature precursor cells in BM biopsy, and the change from WT1-positive to negative status following micro-transplantation. It was also notable that the patient showed no evidence of acute or chronic GVHD. In contrast, in a study including 18 patients with malignant tumor who received allogeneic leukocyte infusion without mobilization, only the four patients who had received auto-HSCT previously developed acute GVHD, while the other 14 cases who did not receive transplantation remained free from acute GVHD. 8 The absence of acute or chronic GVHD in this patient suggests that G-CSF-mobilized PMNCs may be safer than non-mobilized PMNCs. The outcome of this case suggests that more clinical trials should be carried out to validate the feasibility and effectiveness of auto-HSCT combined with micro-transplantation for the treatment of patients with acute leukemias who are not suitable for allo-HSCT, especially those patients with AML of high or intermediate risk, but lack a HLAidentical related or unrelated donor, or those who are too old to undergo allo-HSCT, but young enough to tolerate auto-HSCT.
